Leukaemia group backs Curis' dual Pi3K/HDAC inhibitor with $4 million
This article was originally published in Scrip
Executive Summary
Curis will be getting a boost of up to $4 million in funding from the Leukemia & Lymphoma Society (LLS), which has agreed to support 50% of the direct development costs for CUDC-907, a oral small molecule dual Pi3K and HDAC inhibitor under investigation as a treatment for patients with B-cell lymphoma and multiple myeloma.